Endothelial JCAD Worsens Acute Ischemic Stroke Outcomes by Enhancing Inflammation in Response to Ischemia/Reperfusion

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2025-02-01 DOI:10.1016/j.jacbts.2024.09.009

Stefano Ministrini MD, PhD , Yustina M. Puspitasari MD, PhD , Georgia Beer MSc , Lena Schwarz MSc , Rebecca Niederberger MSc , Simon Kraler MD, PhD , Florian A. Wenzl MD , Mira Katan MD, PhD , Marco Bacigaluppi MD, PhD , Aurora Semerano MD , Alexander Akhmedov PhD , Susan Bengs PhD , Fabrizio Montecucco MD, PhD , Thomas F. Lüscher MD, PhD , Giovanni G. Camici PhD , Luca Liberale MD, PhD

{"title":"Endothelial JCAD Worsens Acute Ischemic Stroke Outcomes by Enhancing Inflammation in Response to Ischemia/Reperfusion","authors":"Stefano Ministrini MD, PhD , Yustina M. Puspitasari MD, PhD , Georgia Beer MSc , Lena Schwarz MSc , Rebecca Niederberger MSc , Simon Kraler MD, PhD , Florian A. Wenzl MD , Mira Katan MD, PhD , Marco Bacigaluppi MD, PhD , Aurora Semerano MD , Alexander Akhmedov PhD , Susan Bengs PhD , Fabrizio Montecucco MD, PhD , Thomas F. Lüscher MD, PhD , Giovanni G. Camici PhD , Luca Liberale MD, PhD","doi":"10.1016/j.jacbts.2024.09.009","DOIUrl":null,"url":null,"abstract":"<div><div>The role of junctional protein associated with coronary artery disease (JCAD) in acute ischemic stroke (AIS) has not been investigated yet. To investigate its potential as a therapeutic target, transient middle cerebral artery occlusion was induced in JCAD knockout mice, with improvement of stroke outcome and reduced blood-brain barrier permeability and expression of vascular cell adhesion molecule (VCAM)-1. JCAD plays a deleterious role in ischemia/reperfusion cerebral damage and associates with higher 90-day mortality in patients with AIS. JCAD may thus represent a novel prognostic biomarker for patients with AIS, as well as a therapeutic target.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 2","pages":"Pages 187-199"},"PeriodicalIF":8.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X24003486","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

The role of junctional protein associated with coronary artery disease (JCAD) in acute ischemic stroke (AIS) has not been investigated yet. To investigate its potential as a therapeutic target, transient middle cerebral artery occlusion was induced in JCAD knockout mice, with improvement of stroke outcome and reduced blood-brain barrier permeability and expression of vascular cell adhesion molecule (VCAM)-1. JCAD plays a deleterious role in ischemia/reperfusion cerebral damage and associates with higher 90-day mortality in patients with AIS. JCAD may thus represent a novel prognostic biomarker for patients with AIS, as well as a therapeutic target.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.